Avanti Biosciences Inc

Avanti Biosciences is a dynamic biotechnology company based at Johnson & Johnson Innovation – JLABS in San Diego, dedicated to transforming treatment landscapes for debilitating diseases.

Our primary focus is fibrotic disorders, including NASH-associated liver fibrosis—affecting ~9–15 million US adults with a market projected to grow from USD 2.32B (2023) to USD 4.51B by 2032—and idiopathic pulmonary fibrosis (IPF), a USD 3B+ market. We also target neurodegenerative conditions (Alzheimer’s, Parkinson’s), inflammatory diseases, and rare metabolic disorders.

By optimizing natural product-derived new chemical entities (NCEs) for enhanced bioavailability and selectivity, we develop innovative therapies for complex diseases.

Our globally recognized scientific founders, backed by >USD 6M in NIH funding, including a recent NIDDK SBIR grant with Ohio State University, drive our mission to address unmet medical needs with cutting-edge solutions.

At a Glance

Private R&D stage biotech company
Research focused on the treatment of unmet medical needs like:
- Idiopathic Pulmonary Fibrosis (IPF)
- NASH-Associated Liver Fibrosis
- Alzheimer's Disease (AD)
- Down Syndrome (DS)
Technology based on natural catechins that are major components of green tea
Research is funded through private funds and NIH grants

At a Glance

Private R&D stage biotech company

Research focused on the treatment of unmet medical needs like:

Idiopathic Pulmonary Fibrosis (IPF)

NASH-Associated Liver Fibrosis

Alzheimer's Disease (AD)

Down Syndrome (DS)

Technology based on natural catechins that are major components of green tea

Research is funded through private funds and NIH grants